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a  b  s  t  r  a  c  t
Objective(s):  We  evaluated  relationships  between  critical  Gag  T-cell  escape  mutations  and concomitant
T-cell  responses  to  determine  whether  HLA-restricted  Gag  mutations  that  confer  protection,  occur  at
similar rates  in a population  infected  with  mixed  HIV-1  clades  A1  and  D  viruses.
Methods:  Assessment  of Gag  selective  pressure,  and  adaptive  T-cell  functions  to  KAFSPEVIPMF  (KF11),
ISPRTLNAW  (ISW9)  and  TSTLQEQIGW  (TW10)  Gag  epitopes  were  combined  with  host  HLA to  assess
correlations  with  rates  of critical  epitope  escape  mutations  in  clades  A1-  (n = 23)  and  D- (n = 21)  infected,
untreated  subjects.  Infecting  clades  and  selection  pressure  were  determined  from  the  gag sequences.
Results:  Overall,  Gag  escape  mutations  A163X  in  KF11  were  detected  in  61%  (14/23)  A1- infected  compared
to  5%  (1/21)  in D-infected  subjects  (p = 0.00015).  Gag  mutations  I147X  in  the  ISW9  epitope  were  seen in
43%:  (10/23)  clade  A  compared  to  5%:  (1/21)  clade  D  infected  subjects,  p = 0.007,  Fisher’s  Exact  test.  Both
mutations  were  more  frequent  in  clade  A1  infection.  Frequencies  of  the measured  epitope-speciﬁc  T-cell
responses  were  comparable  across  clades.  Peptide  binding  afﬁnities  for the  restricting  HLA  alleles  did
not differ  across  clades.  Overall,  selection  pressure  on  the  Gag  protein  was  signiﬁcantly  greater  in clade
A  than  in  clade D  sequences.
Conclusions:  These  ﬁndings  imply  that  HIV-1  vaccine  strategies  designed  to target  structurally  constrained
T-cell  epitopes  may  be further  challenged  by  clade-driven  outcomes  in  speciﬁc  HLA-restricted  Gag  epi-
topes.  Equally,  the  data  are line  with  slower  HIV-1  disease  progression  in  clade  A infection;  and  raise
hope  that  increased  selective  pressure  on  Gag  may  be protective  irrespective  of  host  HLA alleles.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
HIV-1 has evolved into distinct clades that inﬂuence disease out-
come differently; for example, infection with HIV-1 clade D results
in faster disease progression than infection with clade A [1–3].
 This manuscript has not been published in its current form or a substantially
similar form. Part of this work was presented as an abstract at the AIDS Vaccine
Conference, Paris, 19–22 October 2009. The abstract from this presentation was
published as “Serwanga J, et al. Differences in patterns of Gag-induced immuno-
genetic pressure occur between clades A and D chronic HIV-1 infection in a Ugandan
population. Retrovirology 2009;6(Suppl. 3):P380 [22 October 2009]”.
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Contrasting outcomes are partly linked to differences in the quality
of induced virus-speciﬁc T-cell responses [4–6]. Protectiveness of
the induced T-cell responses is partly linked to the superior secre-
tion of HIV-speciﬁc Perforin, polyfunctionality of the responses
[5,7–9] and greater targeting of Gag [5,10,11]. The Gag p24 region
is highly immunogenic, but structurally constrained. Immune pres-
sure on Gag p24 epitopes yields critical epitope escape mutations
[11–13] that impair virus replication, affording survival advantage
to infected hosts [5,10,14] and vaccine recipients [15]. Host HLA B
alleles exert the greatest inﬂuence on HIV-1 disease outcome; HLA
B*57 and B*5801 alleles are associated with slower disease pro-
gression [16–18]. Of the HLA alleles studied in Caucasian, African,
Asian, and Hispanic populations to date, HLA B*57 imparts the
greatest impact on virological control [19]; this outcome is largely
http://dx.doi.org/10.1016/j.vaccine.2015.02.037
0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Characteristics of the study populations and their infecting viruses. This table illustrates characteristics of the study participants. Sequence variations in key Gag epitopes
KAFSPEVIPMF (KF11) residues 162–172; ISPRTLNAW (ISW9), residues 147–155 and TSTLQEQIGW (TW10) residues 240–249 are compared. Horizontal boxes highlight
peptides that elicited IFN- response in that patient. Spot Forming Units per million PBMCs are indicated for cases where interferon (IFN)- responses were detected. HLA
alleles  known to present KF11, ISW9 and TW10 epitopes are highlighted in bold. Induced Spot forming units are highlighted in bold for two cases where IFN- responses
were  maintained despite the presence of an A163X escape mutation.
achieved through T-cell targeting of Gag TSTLQEQIAW (‘TW10′, Gag
240–249), KAFSPEVIPMF (‘KF11′, Gag 162–172) epitopes [20].
Gag-associated protection is partly achieved through target-
ing the conserved and highly constrained KAFSPEVIPMF (KF11),
ISPRTLNAW (ISW9) and TSTLQEQIGW (TW10) [11,12,21] Gag p24
epitopes; yielding critical escape mutations that reduce virus repli-
cation [11–13,21]. The TW10 response dominates in acute HIV
infection of HLA B*57 and B*5801 subjects yielding T242N muta-
tions that are associated with lower viral loads over time [22,23].
Reversion of the transmitted T242N to wild-type sequence implies
that this mutation affects virus ﬁtness [24]. The KF11 epitope
sequence is identical in both clades A and D consensus sequences.
In subjects with presenting alleles, chronic infection is dominated
by the HLA-B*57-restricted KF11 response and consequent A146X
escape mutations that impair virus replicative ability [12,13,24].
Effects of the A163X are partially compensated for by a subsequent
S165N substitution [25].
HLA-restricted imprints in structurally compromised epitopes
would be expected to follow predicted patterns in subjects with
the same presenting alleles; however, this has not always been
the case [26,27]. It is not clear how concurrent T-cell responses
are attributable to this outcome. Here, we combined adaptive T-
cell responses, host HLA alleles and the KF11, ISW9 and TW10
epitope sequences to evaluate how frequencies of critically rel-
evant epitope escape correlate with concurrent T-cell responses
across clades A and D infection among subjects living in the same
environment.
2. Methods
2.1. Study population and evaluation of immune responses
HIV-1 infected, therapy-naïve subjects were recruited for a cross
sectional evaluation. Participant plasma viral loads (HIV RNA copies
per ml), CD4+ T-cell counts (cells/l)  and HLA alleles were deter-
mined as previously described [10]. Infecting clades, estimation
of selection pressure and KF11, ISW9 and TW10 epitope diver-
sities were determined from the gag sequences. Cryopreserved
peripheral blood mononuclear cells (PBMC) from 44 subjects were
initially evaluated for IFN- response to KF11, ISW9 and TW10,
Table 1. Sixteen subjects were further assessed for simultaneous
secretion of IFN-, IL-2, TNF- and Perforin in response to KF11,
ISW9 and TW10, using intracellular cytokine staining assay. Selec-
tion for ﬂowcytometry evaluations was  based on cell availability,
presence of A163G mutations in the KF11epitope and/or posses-
sion of HLA B*57 or B*5801 alleles. Uganda Virus Research Institute
Ethics Review Board and the Uganda National Council of Science
and Technology reviewed and approved this study. All subjects
provided written informed consent for collection and subsequent
evaluation of their specimens.
2.2. Estimation of synonymous (dS) and non-synonymous (dN)
rates
Selective pressure was computed from the rates of non-
synonymous (dN) and synonymous (dS) substitutions. The
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contributions of dN and dS rates to the overall substitution rate
were estimated based on the posterior substitution rates esti-
mated by Bayesian analysis. Their estimation was performed using
a local codon model, as implemented in HYPHY [28]. We  used the
MG94xHKY85 codon model [29], an extension of the classical MG94
model with estimation of equilibrium codon frequencies, using
nucleotide frequencies speciﬁc to each codon position.
2.3. HIV-1 Gag peptides
Peptides used in the Interferon (IFN)-  ELISpot assays
were 15 amino acids (a.a) long and overlapped by 10 a.a
(https://www.aidsreagent.org/Index.cfm). They encompassed HIV-
1 Gag HXB2 residues: (a) 162–172 (KAFSPEVIPMF, designated
KF11; (b) 147–155 (ISPRTLNAW, designated ISW9); and (c)
240–249 (TSTLQEQIGW, designated TW10). United Peptide Biosys-
tems, Inc designed the ﬂowcytometry peptides that represented
circulating variants of KF11, ISW9 and TW10. These peptides
comprised wild type KAFSPEVIPMF (KF11-1) epitope and three
variants KGFSPEVIPMF (KF11-2); KAFNPEVIPMF (KF11-3); and
RGFSPEVIPMF (KF11-4)]; wild type ISPRTLNAW epitope desig-
nated (ISW9-1) and one variant ASPRTLNAW designated (ISW9-2)];
and wild type TSTLQEQIGW epitope (TW10-1) and one variant
TSNLQEQIGW designated (TW10-2)]. Individual peptides were
used at a ﬁnal concentration of 1 g/ml in all PBMC stimulations.
2.4. The ELISpot assay
Virus-speciﬁc IFN- responses were quantiﬁed using ELISpot
assay, as previously described [30]. Responses were enumerated
as spot forming units per million PBMCs (SFU/106 PBMCs). The test
acceptance criteria were: ≥300 SFU per PHA well; ≤100 cumula-
tive spots in all the six background wells; and ≤5 cumulative SFU
in the two wells that contained media only. Test wells with ≥100
net SFU/106 PBMCs after subtracting three times the background
were considered positive.
2.5. Functional avidity of the KF11 peptides
The IFN- ELISpot assay was used to evaluate ﬁve HLA B57 sub-
jects for binding afﬁnities to the 11-mer KF11 peptide; the study
subjects were selected based on PBMC availability. Binding afﬁni-
ties were determined using duplicate 2-fold serial peptide dilutions
ranging from 2 g/ml to 4 pg/ml), as described elsewhere [31].
Peptide concentrations that yielded half the maximum number
of sport forming units were determined from a sigmoidal dose-
response curve ﬁt using Graph Pad Prism 5. Functional avidities
were expressed as half-maximal stimulatory peptide doses (SD
50%).
2.6. Fluorochrome antibodies
Dead cells, B-cells, and monocytes were excluded using
Aqua (L34957, Invitrogen), CD19 APC Alexaﬂuor750 (1072337A,
Invitrogen) and CD14 APC Alexaﬂuor750 (773927B, Invitro-
gen) antibodies, respectively. T-cells were deﬁned using CD3
(brilliant violet 570, B152103, Biolegend), CD8 (paciﬁc blue,
22416, BD Bioscience) and CD4 (PE-Cy5.5, 1049514A, ebio-
sciences) surface staining antibodies. We  deﬁned CD4+ T-cells as
the CD3+CD8−CD4+ T-cell phenotype, and CD8+ T-cells as the
CD3+CD4−CD8+ T-cell phenotype. Virus-speciﬁc CD4+ and CD8+
T-cell responses were determined using intracellular staining for
IFN- (Alexaﬂuor 700, 21128, BD Biosciences); IL-2 (APC, 341116,
BD Biosciences); Perforin (FITC B-D48 clone, F111124, Diaclone);
and TNF- (PE-Cy7, E07677-1632, ebiosciences). Simultaneous
secretion of IFN-, IL2, Perforin and TNF- in response to stimula-
tion with the respective HIV-1 peptides was  measured. We  deﬁned
polyfunctionality as the concurrent secretion of three or more T-cell
functions.
2.7. Intracellular cytokine staining assay
HIV-speciﬁc T-cell polyfunctional responses were assessed
using intracellular cytokine staining assay, as previously described
[32], but with slight modiﬁcations. Brieﬂy, thawed and rested
PBMCs were incubated with 1 g/ml peptide for 6 h at 37 ◦C in a
5% CO2-in air, humidiﬁed environment, in the presence of Golgi
PlugTM and CD28/CD49d co-stimulatory antibodies. Negative con-
trols were PBMCs incubated as above but without peptides. Positive
controls were PBMCs incubated with Staphyloccoccus enterotoxin
B (SEB) instead of peptides. Stimulated PBMCs were then washed
in 10% FBS in PBS, and incubated with Aqua viability dye before
surface staining for T-cell lineage markers. The PBMCs were sub-
sequently intracellularly stained, for the simultaneous expression
of Interferon (IFN)- IL and Perforin. Flowcytometry data was ana-
lyzed using FlowJo (version 9.5.3, TreeStar), Pestle (version 1.6.2)
and SPICE (Version 5.3101) [33] software. The gating strategy for
deﬁnition of IFN-, IL-2, TNF  and Perforin is illustrated in Supple-
mentary Fig. 1.
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2015.02.037.
2.8. Statistical analysis
Statistical analyses were performed using Stata V 10.0 soft-
ware (Stata Corp, TX, USA) and Graph Pad 5.0 (GraphPad Software,
Inc., San Diego, CA, USA). Graphical presentations were performed
using SPICE and Graph Pad software. Continuous data is presented
as medians, with their interquartile ranges (IQR). Medians were
evaluated using Mann Whitney test if there were two groups; or
Kruskal–Wallis Rank Sum test if there were more than two groups.
Proportions were compared using the Fisher’s Exact test. Means
were compared using the Student’s t-test. p values ≥0.05 were
considered signiﬁcant.
3. Results
3.1. Cohort characteristics and infecting HIV-1 clades
The study evaluated 14 males (28%) and 36 females (72%). Their
median age was 37 years (IQR 31–41), median CD4+ T-cell counts
were 538 cells/l (IQR 484–647) and median plasma viral loads
were 15,550 RNA copies/ml (IQR 3450–52,400). Infecting HIV-1
clades based on the gag gene were 46% A1 (23/50), 42% D (21/50),
6% CRF10 CD (3/50), 2% A1/C (1/50), 2% C (1/50) and 2% unclas-
siﬁable (1/50); GenBank accession numbers HQ702686-HQ702731
[10]. Plasma viral loads and CD4+ T-cell counts were relatively sim-
ilar across clade A1-infected subjects (12700; 2280–73600 RNA
copies/ml) and 510; IQR 444–578 CD4+ T-cells/l); and clade D
infected subjects (13100; 6070–162000 RNA copies/ml) and 579;
IQR 487–650 CD4+ T-cells/l, respectively. The WHO  clinical clas-
siﬁcations of HIV-1 infection were 24% (12/50) stage I, 64% (32/50)
stage II and 12% (6/50) stage III. All subsequent analyses are based
on 44 subjects that were infected with clades A1 (n = 23) and D
(n = 21), Table 1.
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Fig. 1. Frequencies of KF11, ISW9 and TW10 epitope variants across clades. This
ﬁgure illustrates frequencies amino acids variation at Gag residues 163 and 165;
Gag residues 146 and 147; and Gag residues 242 and 243. Frequencies of the A163X
mutation (where X = G, V or S at residue 163), (A) I147X mutation (where X = L, V,
F,  W or M at residue 147), (B) and the T242X mutation (where X = N or S), (C), are
compared in clades A1 (n = 23) and D (n = 21) subjects. Compensatory mutations
linked to the above escape mutations are also illustrated.
3.2. The KF11 epitope escape A → X at Gag position 163 (A163X)
was associated with clade A1 infected subjects irrespective of host
alleles
The KF11 amino acid sequences in this population were identical
to the corresponding HXB2 epitope sequences in both clades A1-
and D-infected subjects. Epitope polymorphisms occurred at the
Serine residue 165 (S165N); and at Alanine residue 163 (A163X)
where Alanine was substituted with Glycine (G: n = 13), Valine (V:
n = 1) or Serine (S: n = 1). The presence of A163X was associated with
clade A1 infected subjects. Overall, A163X was found in 15 of 44
subjects (34%); comprising 61% (14/23) clade A1 and 5% (1/21) clade
A
B
Fig. 2. HIV-speciﬁc T-cell responses to KF11 epitope variants were detectable in
subjects with A165X. This ﬁgure illustrates expression of HIV-speciﬁc IFN-, IL-
2,  TNF- and Perforin responses to four KF11 epitope variants in allele-restricting
subjects possessing the A165X mutation. Simultaneous detection of four, three, two
and one HIV-speciﬁc functions (IFN-, Perforin, lL-2 and TNF-) is evaluated in CD4+
and  CD8+ T-cells of HLA B57*/5801 subjects (A and B).
D; p = 0.00015, Fisher’s Exact test, Fig. 1A. Of  the 8 HLA B*57/5801
subjects, A163X occurred in 80% clade A1 (4/5) compared to 0% in
clade D (0/3); p = 0.03, Table 1. Compensatory mutation S165N is
known to partially restore A163X-associated impairment of virus
replication [25]. Overall, S165N mutation was less frequent (5%,
2/44). Of 2 subjects with S165N, the clade D infected subject had
higher plasma viral loads (UG017; 178,000 RNA copies/ml) than the
clade A subject (UG065; 4240 RNA copies/ml).
3.3. I147X compensatory mutation in the ISW9 epitope was more
frequent in clade A1-infected patients
ISW9 epitope polymorphisms comprised the A146X escape in
the epitope ﬂanking region (X = G [2], N [3], P [6], S [1] or V [1]); and
the I147X compensatory mutations (where X = V [8], F [1], W [1] or
M),  that are known to restore immune recognition of ISW9 (29). The
presence of Leucine (L) instead of Isoleucine (I) at Gag residue 147
was consensus in sequences from both the clades A- and D-infected
subjects. Therefore, I147L is not considered to be a polymorphism
in our I147X analyses. Overall, I147X was found in 25% (11/44) sub-
jects, comprising 43% (10/23) clade A1 infected, and 5% (1/21) clade
D infected, irrespective of host HLA alleles; p = 0.007; Fisher’s Exact
test, Fig. 1B. Polymorphism A146X was found in 13/44 (30%) sub-
jects, and occurred at comparable frequencies across clades A1-
(30%, 7/23) and D (29%, 6/21), Table 1.
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Fig. 3. Virus-speciﬁc CD8+ T-cell polyfunctionality was not superior in A163X-bearing, clade A-infected HLAB*57 subjects. Subject PBMCs were stimulated with pooled KF11
variants, and assessed for the simultaneous expression of IL-2, IFN-, TNF- and Perforin, Antigen-speciﬁc IL-2-secreting cells CD8+ T cells were delineated using Boolean
gating. The contribution of Perforin, IFN- and TNF- to the total response was then evaluated on the deﬁned virus-speciﬁc IL-2 secreting T cells. Polyfunctionality was
deﬁned as the simultaneous expression of three or more functions. These pie charts show average HIV-speciﬁc CD3+CD4-CD8+T-cell functions stratiﬁed by IL-2+ secreting
T-cells. Three subjects: (i) UG006 (HLA B*5702, clades D, A), (ii) UG007 (HLA B*5702/03, clades D, B) and (iii) UG060 (HLA B*5704, clades A1, C) are indicated. Pie slices
show  proportions of CD8+ T-cells that concurrently express four (light blue), three (dark blue), two  (light brown) and one function (dark brown). Pie arcs represent exclusive
contributions of Perforin, TNF- or IFN- to the total response within IL-2 secreting HIV-speciﬁc CD8+ T cells. For each subject, overall contribution of virus-speciﬁc Perforin
T-cells  is indicated above the corresponding pie chart. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web  version of this
article.)
3.4. Mutations in the TW10 epitope occurred at comparable
frequencies across clades
Polymorphisms in the TW10 epitope included escape mutation
T242X in 16% of the subjects (where X = N [n = 4] or S [n = 3]); and the
compensatory mutation G248X seen in 39% of the subjects (where
X = A [n = 15], Q [n = 1] or T [n = 1];), Table 1. There was  no signiﬁ-
cant difference between frequencies of T242X ([4%; 1/23] vs. [29%;
6/21]) and G248X ([30%; 7/23] vs. [48%; 10/21]) across clades A1
and D, respectively, Fig. 1C.
3.5. KF11-, ISW9- and TW10-induced IFN- frequencies were
comparable across clades
Of 44 subjects, 6 (14%), 10 (23%) and 1 (2%), had measurable
IFN- responses to ISW9, KF11 and TW10, respectively (Table 1).
The proportion of subjects targeting KF11 and ISW9 did not sig-
niﬁcantly differ across clade A1 (5/23 and 3/23) and clade D (5/21
and 3/21), respectively. In 10 subjects that targeted KF11, median
IFN- magnitudes determined by ELISpot, were comparable across
clade A1 (1875: IQR 820–2105 SFU/106 PBMCs) and D (940: IQR
645–3810 SFU/106 PBMCs), p = 0.75, Mann Whitney test. Similarly,
in 6 responders to ISW9, median IFN- magnitudes did not sig-
niﬁcantly across clade A1 (190; IQR 125–515 SFU/106 PBMCs) and
clade D (130; IQR 110–3593 SFU/106 PBMCs); p = 0.83, Mann Whit-
ney test. Two of eight subjects with HLA B*57 and *5801 and A163X
had detectable HIV-speciﬁc IFN- responses. Median plasma viral
loads were signiﬁcantly lower in the subjects with detectable IFN-
 responses (1814; IQR 488–3140 RNA copies per ml)  compared
to those without (14050; IQR 11600–27200 RNA copies per ml);
p = 0.045, Kruskal–Wallis rank test.
3.6. In HLAB*57 subjects with the A163X mutation, virus-speciﬁc
CD8+ T-cell polyfunctionality were at similar frequencies across
clades
In HLA B*57/*5801 subjects, measurable CD4+ T-cell responses
(Fig. 2A) and CD8+ T-cell responses (Fig. 2B) were detected at
varying frequencies against at least one KF11 variant. Assessment
of the relationship between host HLA B alleles, possession of A163X,
and the associated KF11-speciﬁc CD8+ T-cell response revealed no
evidence for superior T-cell response(s) in clade A1- than clade
D-infected subjects. Overall, frequencies of the detected virus-
speciﬁc Perforin and CD8 + T-cell polyfunctionality were equivalent
or higher in some clade D infected individuals (Fig. 3A and B, respec-
tively) compared to A1 subjects (Fig. 3C).
The CD8+ T-cell response to wild type KF11 (KF11-1) were of
comparatively lower frequencies in both clade A infected (Fig. 4A
and B) and clade D infected subjects (Fig. 4C and D). Secretion of
TNF- dominated the CD8+ T-cell response, while IFN- responses
were marginal or absent. Wild type KF11 responses were largely
monofunctional and lacked Perforin. On the other hand, vari-
ant responses were more polyfunctional and were detectable at
comparable frequencies in both clades A1 and D subjects. Taken
together, these data do not suggest any evidence for superiority of
T-cell responses to KF11 in clade A1 infected patients compared to
clade D infected patients.
3.7. Clade A sequences were subjected to greater selective
pressure than clade D sequences
We  then evaluated the rates of non-synonymous (dN) and syn-
onymous (dS) substitutions, as a measure of the selection pressure
on the clades A and D Gag protein sequences, Fig. 5. The dN/dS
ratio provides a measure of the selection pressure to the refer-
ence sequence. We  found four positively selected sites, and 79
negatively selected sites in clade A sequences; while clade D had
eight and 67 selected sites, respectively, 0.1 signiﬁcance level.
There was  signiﬁcantly more negative selection in clade A [mean
dN/dS ratio 0.328214 (95% CI = [0.29962,0.358633]) than in clade
D [mean 0.438708 (95% CI = [0.407466,0.471585]) sequences, con-
tinuous extension of the binomial distribution test, p = 5 × 10−7
(<0.005). We  also observed an overall low synonymous substitu-
tion rate for HIV-1 clade A, which is known to be less pathogenic
than HIV-1 clade D.
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Fig. 4. Polyfunctional T-cell responses to the KF11 epitope variants were detected at comparable frequencies across clades. This ﬁgure illustrates concurrent expression
of  IFN-, Perforin and TNF- within virus-IL-2-secreting virus-speciﬁc CD8+ T-cells following stimulation with KF11-1 (blue bars), KF11-2 (red bars), KF11-3 (green bars)
and  KF11-4 peptides (orange bars). Distribution of 8 distinct functional subsets in one clade A1, B*5704 subject is illustrated (A). The x-axis represents positive (+) and
negative (−) responses within each combination of IFN-, Perforin and TNF- functional subset. The y-axis represents the percentage of IL-2-secreting virus-speciﬁc CD8+
T-cells  contributing a given functional subset. Bars and error bars indicate means and standard deviations, respectively. Pie charts compare the average functionalities of
IL-2  secreting; virus-speciﬁc CD8+ T-stratiﬁed according to the four KF11 variants (B). Polyfunctionality was deﬁned as the concurrent expression of ≥3 functions. Pie slices
denote  proportions of CD8+ T-cells co-expressing 4 (light blue), 3 (dark blue), 2 (light brown) and 1 function (dark brown). Percentages of IL-2 secreting polyfunctional
CD8+  T-cells are given above each pie. Pie arcs represent proportions of the CD8+ T-cell response containing Perforin (purple arcs), TNF- (green arcs) and IFN- (red arcs).
Likewise, relative contributions (C) and proportions (D) of virus speciﬁc CD8+ T-cells in IL-2 secreting subsets are illustrated in one clade D-infected, HLA B*5702 subject.
(For  interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
3.8. Binding afﬁnity to the KF11 epitope was comparable across
clades A and D
We  ﬁnally evaluated whether clades A- and D-infected, HLA
B*57 subjects differed in KF11 functional avidity. We  detected
varying levels of IFN- responses to KAFSPEVIPMF (KF11-1), KAFN-
PEVIPMF (KF11-3) and RGFSPEVIPMF (KF11-4) peptides in clade A
(Supplementary Fig. 2A and B) and D (Supplementary Fig. 2C–E).
Some low-grade ELISpot titres were observed in both clades. Wild
type KF11 responses were of higher avidity than mutant responses,
Supplementary Fig. 3A and D, clades A and D respectively. Sigmoid
curves from two datasets that showed more robust IFN- responses
(Fig. 2B and E) revealed no difference in functional avidities across
clades A and D, Supplementary Fig. 3.
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2015.02.037.
4. Discussion
The greatest impact on HIV disease may  be mediated by
HLA B-restricted induction of effective virus-speciﬁc CD8+ T-cell
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Fig. 5. Rates of immune pressure across clades A and D sequences. This ﬁgure compares rates of non-synonymous (dN) and synonymous (dS) substitutions along the Gag
protein codons, as a measure of immune selection pressure on clade A (A) and clade D (B) Gag protein sequences. Estimates of the phylogeny (topology and branch) and the
codon-based substitution Bayesian model are shown. Total substitution rate and 95% CI for the posterior distribution estimated in the Bayesian Markov chain Monte Carlo
(MCMC) analysis for clades A and D Gag sequences are illustrated.
responses to certain Gag T-cell epitopes [18]. The resultant pro-
tection is achieved through selective pressure [10,11,18,21] on
the structurally constrained ISW9, KF11 and TW10 Gag p24 CD8+
T-cell epitopes, generating variants with impaired replicative abil-
ity [11,12,34,35]. Ugandan is concurrently infected with nearly
equal proportions of co-circulating clades A and D viruses [36].
We evaluated whether these virus variants that confer appar-
ent advantage to hosts, accumulate at similar frequencies across
clades A and D infection; and determined how frequencies of
those variants correlate with the concomitant T-cell responses.
We combined measurements of adaptive T-cell functionality
with ISW9, KF11 and TW10 Gag p24 epitope sequence data to
demonstrate that the A163X mutation in KF11 was more associ-
ated with clade A1-infection; the compensatory mutation I147X,
known to restore immune recognition of the ISW9 epitope [37],
was more frequent in clade A1 subjects; but frequencies of
TW10 epitope polymorphisms did not signiﬁcantly vary across
clades.
Accumulation of HLA-restricted mutations in HLA matched
hosts has been demonstrated before [38,39]. In matched hosts,
HLA-B*57-restricted A163X escape mutation in the KF11 epi-
tope has been shown to result in reduced plasma viral loads
[11,40]; while I147X compensatory mutation has been linked to
restoration of ISW9 epitope recognition [37]. Structurally con-
strained Gag p24 T-cell epitopes would be expected to yield similar
escape pathways in allele presenting subjects. However, only a
third of HLA matched hosts mount an epitope-speciﬁc response
[41]; and the six major MHC  determinants of HIV-1 protection in
Caucasians [42] lacked protective associations in African cohorts
[26]. It is also unclear why  the widely protective HLA B*5801
[18,43,44] lacked protection in clade A-infected Rwandans [45].
Others also demonstrated higher A163X frequencies among clade
A subjects [27]. However, it remained unclear whether this out-
come depended on differences in concurrent adaptive responses.
The higher rates of A163X mutation observed in HLA matched
and mismatched clade A1 subjects in our population suggest bet-
ter tolerance of those changes by clade A viruses. Differential
clade-based outcome was also reported in clades B and C infected
populations; where it was linked to functional constraints imposed
by HIV clade on speciﬁc Gag residues [46]. Here, we  found evi-
dence for greater selective pressure on clade A Gag compared
to clade D Gag; implying that the clade-speciﬁc outcome were
linked to differences in immune pressure on the infecting virus
clades. These ﬁndings are in line with those recently reported,
which demonstrated clade-associated superior targeting of Gag
among clade C- compared to clade B-infected, HLA B*0702 subjects
[47].
Indisputably, T-cells exert strong selection pressure on HIV-1,
generating HLA allele-restricted mutants that evade subsequent
T-cell responses [48,49]. Emergence of HLA-B*5701-restricted
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variants has been linked to superior maintenance of IL-2 and Per-
forin, and persistence of polyfunctional CD8+ T-cell responses [50].
Superior virological control has been linked to greater functional
avidity of the T-cell responses [31]. Here, we found no evidence for
lower KF11 binding afﬁnities to clade D peptides. However, avidity
comparisons reported here needs to be interpreted with caution,
as there were limitations of sample size. A larger sample size will
be required to adequately evaluate relationships with functional
avidity. In this study, plasma viral loads were eight-fold lower
in presenting hosts bearing the A163X mutation suggesting the
likelihood for potential T-cell involvement. The evaluated epitope-
speciﬁc IFN- and polyfunctional responses were similar across
clade A1 and D suggesting that clade-speciﬁc variations observed
were not merely due to differences in the adaptive T-cell responses
assessed here. The detected preservation of wild-type KF11 despite
existence of epitope-speciﬁc polyfunctional CD8+ T-cell responses
suggests that either the responses to clade D infection was  ineffec-
tive or the virus was less tolerant of the mutations. We  observed
that responses to mutant epitopes were polyfunctional, while CD8+
T-cell polyfunctionality to the wild type epitopes had diminished.
Possibly the responses were exhausted; specimen limitations did
not allow for evaluation of exhaustion status of the antigen-speciﬁc
T-cells. It is not surprising that we detected few TW10 directed epi-
tope escape. The evaluated subjects were all chronically infected;
yet TW10 epitope is targeted by acute CD8+ T-cell responses while
the B*57-restricted KF11 epitope is dominant in chronic infection
[18].
Overall, association of clade A1 subjects with escape mutations
that are known to confer protection supports the notion that clade
A infection with slower disease progression than D [1–3,10]. Over-
all, the data also support others that linked Gag targeting with
improved outcome [10]. While the associations we report here are
signiﬁcant, there were some limitations. First of all, a longitudinal
follow up would have better enabled evaluations of relationships
between the various factors and the trends in evolutionary path-
ways. Secondly, these subjects were randomly selected for HLA
B*57/5801 expressions without bias; ﬁnding of such associations
in relatively few subjects suggests prevailing circulation of KF11
polymorphisms in clade A1-infected populations. However, a larger
cohort will possibly allow for evaluation of correlations with rarer
determinants. Lastly, further studies will be necessary to evalu-
ate how these persistent dominant antigenic stimulations translate
into T-cell exhaustion.
Overall, these data imply that the existing obstacles to HIV T-
cell based vaccines may  be further complicated by clade-associated
differences in selective pressure on known HLA associated Gag out-
comes. Even if critical epitopes remained as targets, their continued
accumulation and adaptation in infected populations may  lower
the cost to viral ﬁtness possibly reducing the host beneﬁt. If the wild
epitopes remain preserved, T-cell responses will likely persist but
may  become exhausted and functionally impaired due to contin-
ued antigenic stimulation. The data also raises hope that increased
selective pressure on Gag will contribute to protection irrespec-
tive of host HLA alleles. The work presented here highlights the
need for improved understanding of how HIV-1 diversity inﬂuences
population-speciﬁc correlates of protection. The data have implica-
tions for T-cell vaccine approaches targeting highly conserved virus
sequences to attenuate the infecting virus, and underscore the need
to understand the direction of virus evolution when designing HIV
T-cell vaccines.
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